Non-small cell lung cancer
Conditions
Interventions
S-1
Sponsors
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.NSCLC with histological proof. 2.Pathological stage IB, II, or IIIA NSCLC (fifth edition of UICC/AJCC 1997) after complete resection. 3.No prior treatment except for surgery. 4.Sufficient oral intake. 5.Performance status (PS) 0 or 1. 6.Patients also had to have adequate organ function (3500 <leukocytes < 12,000/mm3; thrombocytes, >100,000/mm3; total bilirubin,<1.5 mg/dl; AST and ALT, less than twice the normal limits at each institution; BUN, <25 mg/dl; creatinine, less than the normal limits at each institution; and creatinine clearance (Ccr))
Exclusion criteria
Exclusion criteria: 1.History of drug hypersensitivity. 2.Contraindication of oral S-1 administration (refer appended papaer). 3.Serious surgical or non-surgical complications 4.Active secondary cancer. 5.Watery diarrea. 6.Pregnant or lactating women. 7.Male who has intension to make pregnant 8.Patient to whom primary doctor judjed inadequate to register.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion rate of scheduled adjuvant chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and grade of adverse reactions. 3-year and 5-year overall survivial. 3-year and 5-year relapse free survival | — |
Countries
Japan
Contacts
Public ContactTomoshi Tsuchiya
Nagasaki University Graduate School of Biomedical Sciences Division of Surgical Oncology
Outcome results
None listed